There has been an increased awareness of the high prevalence of celiac disease and increasing suggestions that this illness is underdiagnosed, particularly in the United States. The potential consequences of underdiagnosis include an increased risk of associated autoimmune conditions. These issues on prevalence and diagnosis are reviewed in detail in the contribution on celiac disease by King and Ciclitira [pp 102-106].
There have also been remarkable advances in our understanding of the pathogenesis of celiac disease. In celiac disease, ingestion of a specific antigen by individuals with a genetic predisposition to mount an abnormal immune response to that antigen results in intestinal inflammation. The inflammatory response in celiac disease is triggered by gliadins, proteins found in wheat, barley, and rye. The genetic predisposition is associated with the HLA-DQ2 locus of the major histocompatibility complex; however, the mechanism by which this specific HLA type contributes to the disease was unknown. Most patients with celiac disease have antibodies to endomysium, a component of the extracellular matrix. Whether these antibodies are involved in inducing tissue injury or are merely markers for the disease was not clear. The endomysial autoantigen was identified as tissue transglutaminase, an enzyme that is secreted by fibroblasts, macrophages, and endothelial cells [1] . However, the mechanism by which gliadin induces the T-cell-mediated immune response seen in celiac disease and how this response is linked to the generation of autoantibodies to tissue transglutaminase was unknown. A recent study by Molberg et al. [2] begins to explain the mechanism of these events. These investigators further define the role of tissue transglutaminase in the pathogenesis of celiac disease and draw together the seemingly unrelated threads of the HLA-DQ2 locus and the IgA antiendomysial antibody and tie them to the mechanism of tissue injury. They demonstrate that deamidation of gliadin by tissue transglutaminase unmasks epitopes that bind HLA-DQ2 on antigen presenting cells. The HLA-DQ2-gliadin epitope complex is recognized by intestinal T-cells from patients with celiac disease. Gliadin-specific T-cell clones were isolated from the intestine and peripheral blood of patients with celiac disease, and proliferation was measured after exposure to gliadin or gliadin plus tissue transglutaminase. The addition of tissue transglutaminase markedly enhanced the proliferative response in clones isolated from the intestine but not in those isolated from peripheral blood.
These investigators also examined the interactions of a peptide derived from gliadin (residues 134-153) with a cell line transfected with the appropriate T-cell receptor and with HLA-DQ2 in an in vitro binding assay. They demonstrated that the deamidation of the gliadin peptide enhanced the binding of the peptide to HLA-DQ2 and provoked a more vigorous T-cell response. This is the first demonstration that deamidation of glutamine can potentiate an immune response to an antigen.
Not only can tissue transglutaminase deamidate gliadin, but it can also become cross-linked to gliadin peptide or to its deamidated variants. Peptides derived from these tissue transglutaminase-gliadin complexes are then displayed by antigen-presenting cells bearing the HLA-DQ2 major histocompatibility antigen. Activation of CD4+ T-cells by presentation of deamidated gliadin or gliadin-tissue transglutaminase complex on HLA-DQ2 can result in differentiation of the lymphocytes down either the Th1 or Th2 pathway. Th1 cytokines, particularly TNF-α, induce fibroblasts to produce metalloproteinases that lead to degradation of the extracellular matrix and loss of epithelial integrity [3] . Differentiation down the Th2 pathway results in B-cell maturation and expansion of plasma cells that produce IgA antibodies against gliadin, tissue transglutaminase, and gliadin-tissue transglutaminase complexes. These antibodies against tissue transglutaminase and gliadin-tissue transglutaminase complexes are the antiendomysial antibodies found in the sera of patients with celiac disease.
If tissue injury in celiac disease were mediated by antibodies to tissue transglutaminase, then one might expect injury in many organs because tissue transglutaminase is widely distributed. However, injury mediated by an immune response to a gliadin-tissue transglutaminase complex would be specific to the intestine. Therefore, the localization of tissue injury in celiac disease to the intestine raises the possibility that the pathogenic immune response is primarily directed against a gliadin-tissue transglutaminase complex rather than against tissue transglutaminase alone.
The IgA response to tissue transglutaminase may contribute to the epithelial destruction and villus atrophy that is characteristic of celiac disease. Antiendomysial (antitissue transglutaminase) IgA from patients with celiac disease blocks the differentiation of T84 cells [4] . Repair of damaged intestinal epithelium is dependent on the activation of transforming growth factor-β (TGF-β) by tissue transglutaminase. The presence of antibodies to tissue transglutaminase may block its ability to activate TGF-β and therefore block the repair of injured epithelium [5] .
A second area of progress in small intestinal research during the past year has been in intestinal permeability. This topic is reviewed in the contribution by Smale, Tibble, and Bjarnason [pp 134-139]. There are tight junctions between epithelial cells in the intestinal mucosa; these tight junctions are not absolutely impermeable, but they allow the passage of some small hydrophilic molecules. The "tightness" of these junctions varies with position on the longitudinal axis (the junctions become tighter distally) and on the vertical axis (villi are tighter than crypts) of the intestine. Permeability is regulated; a number of mediators, including acetylcholine and prostaglandins, affect permeability. Gastrointestinal diseases such as celiac disease, Crohn's disease, and various enteric infections are associated with increased permeability. In intestinal permeability studies, test markers are administrated into the lumen, pass between epithelial cells, and are excreted in the urine. Increased permeability is associated with increased passage of test compounds between epithelial cells and increased accumulation in the urine. A third area of small intestinal research to show significant progress in the past year is that of small intestinal motility, particularly as it relates to serotonin and irritable bowel syndrome. Advances in the role of serotonin or 5-hydroxytryptamine (5-HT) in the intestine are reviewed in the contribution by Gershon [pp 113-120]. 5-HT is secreted by enterochromaffin cells of the intestinal mucosa and stimulates the mucosal processes of intrinsic and extrinsic primary afferent neurons. The secretion of 5-HT, a neurotransmitter, by enterochromaffin cells allows the mediation of neural reflexes in the gut without any input from the brain or spinal cord. The intrinsic primary afferent neurons, which are activated by 5-HT 1 1P P/ /4 4 receptors, initiate peristaltic and secretory reflexes. Extrinsic nerves, which carry signals to the central nervous system, are activated by 5-HT 3 receptors. In the mucosa, 5-HT is inactivated by uptake into epithelial cells by the serotonin reuptake transporter (SERT), an integral membrane protein [7] .
Epithelial SERT is the same molecule that transports 5-HT in the central nervous system and is inhibited by SSRIs (serotonin selective reuptake inhibitors), which are used in the treatment of depression and other psychiatric disorders.
Irritable bowel syndrome, which is marked by abdominal cramps accompanied by either constipation or diarrhea, is a common condition affecting up to 20% of the population in the United States. No definitive anatomic or chemical defects have been identified in irritable bowel syndrome. Although the pathogenesis of irritable bowel syndrome is unknown, the possibility that an abnormality related to 5-HT is involved in its pathogenesis has been suggested. The association of 5-HT with irritable bowel syndrome is supported by the suggestion that SSRIs [8] , 5-HT 3 receptor antagonists [9] , and 5-HT 4 receptor antagonists [8] may all be useful in the management of this disorder. SSRIs have been used to treat irritable bowel syndrome, and it is likely that their therapeutic effects in this condition relate to their effects on SERT in the intestine rather than on SERT in the central nervous system. Activation of 5-HT 3 receptors on extrinsic afferent fibers may give use to visceral hypersensitivity. 5-HT 3 receptors are also expressed by most myenteric neurons, including those that activate gastrointestinal muscle; activation of 5-HT 3 receptors on motor neurons may give use to abnormal motility. A contribution of enteric 5-HT to the pathogenesis of irritable bowel syndrome is supported by the finding that patients with diarrhea-predominant irritable bowel syndrome have an abnormally large postprandial release of 5-HT from the bowel that is detectable in the blood [10] . Alosetron, a 5-HT antagonist, increases the abnormally low compliance in irritable bowel syndrome. In clinical trials, alosetron produced statistically signifi-cant improvements in abdominal pain, stool frequency, stool consistency, and urgency in women with irritable bowel syndrome [9] . The major adverse event with alosetron was constipation, an expected effect of 5-HT 3 antagonists. The studies defining the role of 5-HT in irritable bowel syndrome may mark the beginning of a more scientifically grounded approach to the treatment of this disorder.
